Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis
Status:
Not yet recruiting
Trial end date:
2022-09-19
Target enrollment:
Participant gender:
Summary
This study is a phase II, multicenter, randomized, double-blind, placebo-controlled, seamless
adaptive design clinical study, aiming to evaluate the safety and effectiveness of three
doses of ASC42 matched placebo in subjects with primary biliary cholangitis.